ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SUN Surgical Innovations Group Plc

0.50
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Surgical Innovations Group Plc LSE:SUN London Ordinary Share GB0004016704 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.50 0.40 0.60 0.50 0.50 0.50 14,313,871 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 11.34M 264k 0.0003 16.67 4.66M

Surgical Innovations Group PLC Distalmotion's Dexter Robot receives CE Mark

08/01/2021 7:00am

RNS Non-Regulatory


TIDMSUN

Surgical Innovations Group PLC

08 January 2021

Surgical Innovations Group plc

("Surgical Innovations", "SI" or the "Company")

Distalmotion's Dexter Robot receives CE Mark

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Distalmotion SA, a Swiss-based medical device company providing robotic surgery systems on a transparent and fair per-procedure cost ("Distalmotion"), has received European CE Mark for its 'Dexter' surgical robot. Manufactured in Switzerland, Dexter combines the affordability of laparoscopy with the benefits of robotic surgery to bring simplicity and versatility in minimally invasive surgical care.

Elemental Healthcare Limited, a wholly owned SI subsidiary, has exclusive UK distribution rights for the Dexter Robot.

The European CE mark remains valid in the UK post Brexit.

Adam Power, SI Group Development Director, commented: "The UK minimally invasive surgical robot market has been dominated by a single, expensive and very complex robot for nearly two decades. Dexter is designed to integrate readily into existing laparoscopic procedures and its simplicity and versatility makes robotics accessible for a wider range of procedures. The regulatory approval of the Dexter operating robot now allows the introduction of a disruptive robotic model to UK healthcare. The ease of use, affordability and Swiss manufacturing excellence will be significant factors in the growth opportunity for this new robot."

Michael Friedrich, CEO, Distalmotion said: "Distalmotion are looking forward to some early successes in the important UK market with our partner, Elemental Healthcare. The NHS is especially appropriate for the Dexter strategic model of selling and we already have hospitals that are some way into the process of product acquisition."

For further information please contact:

 
 Surgical Innovations Group plc                              www sigroupplc com 
 David Marsh, CEO                                            Tel: 0113 230 7597 
 Charmaine Day, Co Sec & GFC 
 
 N+1 Singer (Nominated Adviser &                             Tel: 020 7496 3000 
  Broker) 
   Aubrey Powell (Corporate Finance) 
 Rachel Hayes (Corporate Broking) 
 
 Walbrook PR (Financial PR & Investor   Tel: 020 7933 8780 or si@walbrookpr.com 
  Relations) 
 Paul McManus / Lianne Cawthorne             Mob: 07980 541 893 / 07584 391 303 
 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.

Further information

Further details of the Group's businesses are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFLDLDIDIIL

(END) Dow Jones Newswires

January 08, 2021 02:00 ET (07:00 GMT)

1 Year Surgical Innovations Chart

1 Year Surgical Innovations Chart

1 Month Surgical Innovations Chart

1 Month Surgical Innovations Chart

Your Recent History

Delayed Upgrade Clock